ProNaGen: Engineering of Recombinant Protein Nanosheet-Based Bioemulsions for Next Generation Bioprocessing and Biomanufacturing

ProNaGen：用于下一代生物加工和生物制造的基于重组蛋白纳米片的生物乳液的工程

• 批准号: EP/Y032667/1
• 负责人: Julien Gautrot
• 金额: $ 16.19万
• 依托单位: Queen Mary University of London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FY032667%2F1
• 关键词: ProNaGen; Engineering; Recombinant; Protein; Nanosheet

An important hurdle to the democratisation of cell therapies and cell-based in vitro models remains our limited ability to scale up and automate cell manufacturing and processing. Whilst solid and hydrogel microcarriers and magnetic microparticles have shown some promise to tackle this pitfall, they remain difficult to process and separate from cell products, lead to potential contamination of the cell mass generated and are associated with high costs. The design of affordable, scalable and regulatory-ready platforms for the culture and processing of adherent cells, yet by-passing the reliance on solid substrates and microcarriers, remains essential for cell manufacturing and will have an important impact on the sustained growth of associated biotech markets. To bypass the contamination of cell products with microplastics or particles, simplify bioprocessing and reduce associated costs, bioemulsions have recently been proposed as attractive alternatives. Although their performance has been demonstrated in a growing number of cases, current protein and polymer nanosheet technologies rely on protein and materials that present a risk for regulatory compliance, for applications in regenerative medicine (including for cell implantation).

细胞疗法和基于细胞的体外模型民主化的一个重要障碍仍然是我们扩大和自动化细胞制造和加工的能力有限。虽然固体和水凝胶微载体以及磁性微粒已显示出解决这一缺陷的一些希望，但它们仍然难以加工和与细胞产物分离，导致产生的细胞团的潜在污染，并且与高成本相关。设计经济实惠、可扩展且易于监管的贴壁细胞培养和加工平台，同时避免对固体基质和微载体的依赖，对于细胞制造仍然至关重要，并将对相关生物技术的持续增长产生重要影响市场。为了避免细胞产品受到微塑料或颗粒的污染、简化生物加工并降低相关成本，生物乳液最近被提议作为有吸引力的替代品。尽管其性能已在越来越多的案例中得到证明，但当前的蛋白质和聚合物纳米片技术依赖于蛋白质和材料，这些蛋白质和材料在再生医学（包括细胞植入）应用中存在监管合规风险。